Test drug XY0206 versus usual salvage chemotherapy for AML
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 study tests whether XY0206 can work better than standard “salvage” chemotherapy in adults whose acute myeloid leukemia (AML) has come back or did not respond to prior treatment. It targets AML with a specific genetic change (FLT3-ITD) and aims to improve outcomes when standard options are limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have AML that is either “primary” or AML related to myelodysplastic syndrome (MDS), confirmed by pathology review.
- Your AML must have relapsed or been refractory after prior AML treatment, including certain patterns of relapse/refractory disease.
- Your leukemia test must show an FLT3-ITD mutation in bone marrow or blood.
- Your heart and organ tests must be acceptable (kidney, liver, bilirubin, and ECG/QTcF).
- You must not have certain other leukemia types or related conditions, and you must meet key safety limits like blood tests and acceptable recovery expectations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
This Phase 3 study compares HEC73543 versus standard “salvage” chemotherapy in adults with AML that has come back or did not respond after first treatment. It’s designed for people whose leukemia has an FLT3-ITD mutation and may help improve response and outcomes.
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a targeted therapy for people with a specific genetic change in their AML cells called FLT3-ITD. It aims to see if adding this targeted drug to standard chemotherapy improves outcomes for patients who are otherwise healthy enough to receive intensive treatment.
Hear when a new Acute Myeloid Leukemia With FLT3/ITD Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.